CaverStem | Stem Cell Treatment
By David M. Odom, MD
On October 18, 2017, Creative Medical Technology Holdings announced the completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company’s patented CaverStem® procedure. Based on the data collected on the trial and there having been no adverse side effects, the procedure has been determined to be safe based on the trial data and the determination from the independent safety monitor. In addition, a similar trial conducted in Europe experienced no adverse or significantly adverse events resulting from the procedure.
In published results from a European trial performing the same procedure on 20 patients concluded, “after 6 months, significant improvements versus baseline were noted”. In addition, “At month 6, all patients described on-medication erections sufficient for penetration”.
First In-Human Proof Of Concept